Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
P649403-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$580.90
|
|
|
P649403-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$880.90
|
|
|
P649403-50mg
|
50mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$2,500.90
|
|
|
P649403-100mg
|
100mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$4,000.90
|
|
| Synonyms | Pelitrexol (USAN/INN) | (2S)-2-(((5-(2-((6S)-2-Amino-4-oxo-1,4,5,6,7,8-hexahydropyrido(2,3-d)pyrimidin-6-yl)ethyl)-4-methylthiophen-2-yl)carbonyl)amino)pentanedioic acid | AG-2038 | PELITREXOL [INN] | NSC767745 | NSC-767745 | Pelitrexol [USAN] | (2S)-2-[[ |
|---|---|
| Specifications & Purity | ≥98% |
| Biochemical and Physiological Mechanisms | Pelitrexol (AG 2037) is an inhibitor of glycinamide ribonucleotide formyltransferase ( GARFT ), a purine biosynthetic enzyme. Pelitrexol also inhibits mTORC1 by reducing GTP-bound Rheb level, a mTORC1 obligate activator. Pelitrexol shows robust tumor grow |
| Storage Temp | Store at -20°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Action Type | INHIBITOR |
| Mechanism of action | GAR transformylase inhibitor |
| Product Description |
Pelitrexol (AG 2037) is an inhibitor of glycinamide ribonucleotide formyltransferase ( GARFT ), a purine biosynthetic enzyme. Pelitrexol also inhibits mTORC1 by reducing GTP-bound Rheb level, a mTORC1 obligate activator. Pelitrexol shows robust tumor growth suppression in mice In Vitro Pelitrexo (150 nM; 24 h) profoundly inhibits mTORC1 activity by reducing intracellular guanine nucleotides level as well as GTP-bound Rheb protein level in A549 cells. Pelitrexo (0-1000 mM; 16 h) strongly inhibits the phosphorylation level of ribosomal protein S6 (S6RP), S6K1, and Chk1 in a dose-dependent manner in NCI-H460 cells. Pelitrexo (100 nM; 48 h) arrests cell cycle at G1 phase in NCI-H460 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cycle AnalysisCell Line: NCI-H460 NSCLC Concentration: 100 nM Incubation Time: 4, 8, 24, 48 hours Result: Resulted 63% cells accumulation in G1 phase of the cell cycle. Cell Cycle AnalysisCell Line: NCI-H460 NSCLC Concentration: 0, 10, 30, 100, 300, 1000 nM Incubation Time: 16 hours Result: Inhibits the level of p-S6RP, p-S6K1, and p-Chk1. In Vivo Pelitrexo (10 mg/kg, 20 mg/kg; i.p.; every 4 days for 3 weeks) provokes both mTORC1 inhibition and robust tumor growth suppression in mice bearing nonsmall-cell lung cancer (NSCLC) xenografts . Pelitrexo (20 mg/kg; i.p.; every 4 days for 3 weeks) inhibits GARFT-dependent purine biosynthesis and blocks mTORC1 function . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Xenograft model of nonsmall-cell lung cancer (NSCLC) in mice Dosage: 10 mg/kg, 20 mg/kg Administration: Intraperitoneal injection; every 4 days for 3 weeks for group 1; administrated at 1, 4, 7 days for group 2 Result: Inhibited tumor growth by 64% and 69% at 10 mg/kg and 20 mg/kg, respectively in group 1. Inhibited mTORC1-dependent phosphorylation of S6K1, S6RP and CAD at 20 mg/kg in group 2. Form:Solid IC50& Target:GARFT |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organic acids and derivatives |
| Class | Carboxylic acids and derivatives |
| Subclass | Amino acids, peptides, and analogues |
| Intermediate Tree Nodes | Amino acids and derivatives - Alpha amino acids and derivatives |
| Direct Parent | Glutamic acid and derivatives |
| Alternative Parents | N-acyl-alpha amino acids Pyridopyrimidines Thiophene carboxamides 2,3,5-trisubstituted thiophenes 2-heteroaryl carboxamides Pyrimidones Aminopyrimidines and derivatives Pyridines and derivatives Dicarboxylic acids and derivatives Vinylogous amides Heteroaromatic compounds Secondary carboxylic acid amides Amino acids Carboxylic acids Azacyclic compounds Primary amines Hydrocarbon derivatives Organic oxides Carbonyl compounds |
| Molecular Framework | Aromatic heteropolycyclic compounds |
| Substituents | Glutamic acid or derivatives - N-acyl-alpha-amino acid - N-acyl-alpha amino acid or derivatives - Pyridopyrimidine - 2-heteroaryl carboxamide - Thiophene carboxamide - 2,3,5-trisubstituted thiophene - Thiophene carboxylic acid or derivatives - Aminopyrimidine - Pyrimidone - Dicarboxylic acid or derivatives - Pyridine - Pyrimidine - Heteroaromatic compound - Vinylogous amide - Thiophene - Amino acid - Carboxamide group - Secondary carboxylic acid amide - Organoheterocyclic compound - Azacycle - Carboxylic acid - Amine - Hydrocarbon derivative - Primary amine - Organooxygen compound - Organonitrogen compound - Organic oxide - Organic oxygen compound - Carbonyl group - Organic nitrogen compound - Aromatic heteropolycyclic compound |
| Description | This compound belongs to the class of organic compounds known as glutamic acid and derivatives. These are compounds containing glutamic acid or a derivative thereof resulting from reaction of glutamic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. |
| External Descriptors | Not available |
|
|
|
| ALogP | 0.7 |
|---|
| IUPAC Name | (2S)-2-[[5-[2-[(6S)-2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]-4-methylthiophene-2-carbonyl]amino]pentanedioic acid |
|---|---|
| INCHI | InChI=1S/C20H25N5O6S/c1-9-6-14(18(29)23-12(19(30)31)3-5-15(26)27)32-13(9)4-2-10-7-11-16(22-8-10)24-20(21)25-17(11)28/h6,10,12H,2-5,7-8H2,1H3,(H,23,29)(H,26,27)(H,30,31)(H4,21,22,24,25,28)/t10-,12-/m0/s1 |
| InChIKey | QXOPTIPQEVJERB-JQWIXIFHSA-N |
| Smiles | CC1=C(SC(=C1)C(=O)NC(CCC(=O)O)C(=O)O)CCC2CC3=C(NC2)N=C(NC3=O)N |
| Isomeric SMILES | CC1=C(SC(=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)CC[C@H]2CC3=C(NC2)N=C(NC3=O)N |
| Alternate CAS | 446022-33-9 |
| PubChem CID | 135431074 |
| MeSH Entry Terms | pelitrexol |
| Molecular Weight | 463.51 |
| Solubility | DMSO : 25 mg/mL (53.94 mM; Need ultrasonic) |
|---|---|
| Molecular Weight | 463.500 g/mol |
| XLogP3 | 0.700 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 9 |
| Exact Mass | 463.153 Da |
| Monoisotopic Mass | 463.153 Da |
| Topological Polar Surface Area | 211.000 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 859.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |